Goldman Sachs Delivers a Blow to Alnylam’s Stock

The biotechnology sector was rattled by an unexpected development yesterday. In a move that caught investors off guard, Goldman Sachs removed Alnylam Pharmaceuticals from its prestigious Conviction List, triggering a sharp decline in the share price of this RNAi therapy pioneer. This decision arrives just days after the company posted exceptionally strong quarterly results, leaving market participants to question whether this analyst action signals deeper concerns beyond temporary market jitters.

Strong Fundamentals Clash with Analyst Sentiment

The timing of Goldman Sachs’ revision appears particularly inopportune. Alnylam had recently dazzled the market with spectacular third-quarter performance, reporting adjusted earnings of $2.90 per share—more than double analyst expectations. Revenue surged to $1.25 billion, with investors particularly encouraged by the performance of the TTR franchise. Driven largely by the blockbuster drug AMVUTTRA, product revenue demonstrated remarkable year-over-year growth, effectively doubling.

Despite these impressive financial metrics, the removal from the Conviction List entirely overshadowed the positive earnings report. This action communicates a revised risk assessment to institutional investors and prompted immediate selling pressure. The stock declined by nearly 5 percent, closing the trading session deep in negative territory.

Insider Transactions and Upcoming Catalysts

Adding to the market’s contemplation, regulatory filings reveal that company executives, including CEO Yvonne Greenstreet, have disposed of shares worth over $44 million during the past 90 days. While such transactions are frequently scheduled in advance, some investors are interpreting these sales in conjunction with Goldman’s decision, creating a cautious narrative.

Should investors sell immediately? Or is it worth buying Alnylam?

The underlying business performance, however, tells a different story. TTR franchise revenue exploded by 135 percent, propelled by AMVUTTRA’s 165 percent growth. Based on this powerful momentum, Alnylam management raised its full-year product revenue guidance to a range between $2.95 and $3.05 billion.

Market attention now shifts to a potentially significant near-term catalyst. Between November 7 and 10, Alnylam is scheduled to present new results from its HELIOS-B Phase 3 study at the American Heart Association Scientific Sessions. In the biotech sector, such clinical data updates traditionally exert substantial influence on share performance, potentially acting as either a brake on the current downturn or an accelerator for recovery.

The broader analytical community maintains a favorable outlook. Twenty-four research analysts continue to recommend a “Buy” rating, with their average price target standing at $480.50. Institutional investors also demonstrate considerable confidence, holding participation rates exceeding 102 percent, which indicates strong belief in the company’s long-term prospects.

The central question for investors is whether Alnylam faces a temporary market correction or the beginning of a more sustained negative trend. The coming days will reveal whether robust fundamental performance or shifting analyst sentiment will ultimately dictate the stock’s direction.